Jacobus J. M. van der Hoeven

Author

Also Known As

Bekelman, Justin E., J J M Koos van der Hoeven, J J M Van Der Hoeven, J J M van der Hoeven, J J van der Hoeven, J. J. M. Van Der Hoeven, J. J. M. van der Hoeven, J.J.M van der Hoeven, J.J.M. (Koos) van der Hoeven, J.J.M. Van Der Hoeven

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Radboud University Nijmegen Leiden University Medical Center Radboud University Medical Center University Medical Center Utrecht

About

Jacobus J. M. van der Hoeven is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	21	1.9K
2	Health Sciences	6	6	526
3	Nursing	1	1	45
4	Public Health	1	1	45
5	Cell Biology	1	1	29

Jacobus J. M. van der Hoeven

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group Lieke H. J. Simkens, Harm van Tinteren, Anne M. May, The Lancet OncologyGastrointestinal OncologyMaintenance TreatmentCancer ManagementColorectal Cancer	2015	511
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen, Nature Communications	2020	320
Biologic Correlates of <sup>18</sup>Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography Reinhard Bos, Jacobus J. M. van der Hoeven, Elsken van der Wall, Journal of Clinical Oncology Breast OncologyOncologic ImagingPathologyTumor BiologyPositron Emission Tomography	2002	320
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer E. M. Dijkgraaf, Saskia J. Santegoets, A.K.L. Reyners, Annals of Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2015	189
Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary Hugo M. Horlings, Ryan K. van Laar, Jan-Martijn Kerst, Journal of Clinical Oncology	2008	184
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer, The Lancet Oncology MedicineClinical TrialsGynecologyBreast CancerAromatase	2017	157
<sup>18</sup>F-2-Fluoro-2-Deoxy-<scp>d</scp>-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer Jacobus J. M. van der Hoeven, Nanda C. Krak, Otto S. Hoekstra, Journal of Clinical Oncology	2004	123
Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients Astrid A.M. van der Veldt, N. Harry Hendrikse, Egbert F. Smit, European Journal of Nuclear Medicine and Molecular Imaging	2010	107
Determinants of Diagnostic Performance Of [F-18]Fluorodeoxyglucose Positron Emission Tomography for Axillary Staging in Breast Cancer Jacobus J. M. van der Hoeven, Otto S. Hoekstra, Emile F.I. Comans, Annals of Surgery	2002	104
Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach Alicia K. Morgans, A.C.M. van Bommel, Caleb Stowell, European Urology	2015	103

Page 1